Remote monitoring of CGM data of children and youth attending diabetes camp has been shown to reduce overall and nocturnal hypoglycemia, compared to treatment decisions based on self-monitored blood glucose (SMBG) values. However, some diabetes camps still require regular SMBG testing. We compared at-home versus at-camp glucose control where CGM data were used as the basis for diabetes treatment decisions. Thirty-four campers with T1D (mean±SD age 12±3 years, A1C 7.5±1.2%) were eligible for inclusion if they were using Control-IQ technology (Tandem Diabetes Care) prior to and during their attendance at Camp Buck, a diabetes-focused facility near Lake Tahoe. At camp, their CGM data (Dexcom G6) were integrated with the CampViews EMR system (Nevada-California Diabetes Association). CGM data from at-home and at-camp intervals were compared. As shown in the Table, mean glucose and overall time in range (TIR, 70-180 mg/dL) improved at camp, with statistical significance in the overnight (10PM-6AM) interval. Although time in Level 1 hypoglycemia increased at camp, there were no significant changes between at-home and at-camp levels of Level 2 hypoglycemia. CGM data can be used nonadjunctively in the camp setting to maintain or improve glycemic control. Centralized remote monitoring of glucose data allows camp attendees and staff to safely reduce or eliminate SMBG testing. Disclosure S.E.Gleich: Research Support; Dexcom, Inc. H.R.Tecca: Employee; Dexcom, Inc. N.D.Gibson-north: None. S.B.Andrade: Employee; Dexcom, Inc. J.Welsh: Employee; Dexcom, Inc. E.Schuster: Employee; Dexcom, Inc. T.C.Walker: Employee; Dexcom, Inc., Stock/Shareholder; Dexcom, Inc.
Background: Safe management of T1D in congregate settings such as diabetes camps may involve continuous glucose monitoring (CGM) devices, and managers of these facilities face choices regarding systems and deployment strategies. We aimed to compare individual versus multiplex monitoring strategies and to separately compare CGM systems from Dexcom (G6) and Abbott (Libre Pro) . Methods: G6 users included 45 campers ages 8-17 years. Four used individual SMBG with G6 Pro systems in blinded mode; 41 used unblinded G6 systems whose data were available for remote review on an investigational multiplex display. Separately, data from 17 campers using G6 systems were compared to data from 17 campers using Libre Pro systems. Results: As shown in the Table, most metrics of glycemic control favored the multiplex-monitored group over the individually SMBG-monitored group; the between-groups difference reached statistical significance with respect to nocturnal percent of time <54 mg/dL (%<54) . Analysis of data from G6 and Libre Pro systems revealed significantly lower mean glucose levels and more hypoglycemia among Libre Pro users, especially at night. Conclusion: Meaningful differences in CGM-measured overall and nocturnal hypoglycemia may result from choices in monitoring strategies and device manufacturers. Disclosure S. E. Gleich: Research Support; Dexcom, Inc. H. R. Tecca: Employee; Dexcom, Inc. N. D. Gibson-north: n/a. E. Schuster: Employee; Dexcom, Inc. C. R. Green: Employee; Dexcom, Inc. T. C. Walker: Employee; Dexcom, Inc., Stock/Shareholder; Dexcom, Inc. Funding Dexcom, Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.